Scientists describe "the moment of Yorka" about how to prevent cancer from increasing

Scientists have described the “moment of Yorka” when they found out how aspirin could prevent some cancers from spreading.

Their new research has been based on existing evidence, which suggests that aspirin supports the body’s immune system to help take deadly cancer cells.

Clinical tests in cancer patients are currently continuing how aspirin can help prevent the return of the disease.

However, experts said cancer patients should not normally take aspirin without talking to their doctor because of potential side effects such as gastric bleeding.

The new work was published in the journal Nature and was provided by the Medical Research Council and Wellcome Trust.

The leadership of the University of Cambridge shows a path for aspirin to become a cancer treatment, along with the creation of more effective medications to prevent cancer.

The researchers showed 810 genes in mice and found 15 cases whose effect is on cancer spread.

Specifically, they found that mice that lack a gene that produce a protein called ARHGEF1 is less likely to spread to cancer in the lungs and liver.

Experts have found that ARHGEF1 suppresses a type of immune cell called T cell, which is important for detecting and killing metastatic cancer cells (expanding to other parts of the body).

They found that when the T cells were exposed to a clot called thromboxan A2 (TXA2), Arhgef1 turned on – it was an unexpected finding for scientists.

The TXA2 is produced by platelets in the blood, and aspirin is now known to reduce TXA2 production.

Research has shown that aspirin can prevent the TXA2 by reducing the headlines – T cells release the T cells from suppressing T cells to eliminate cancer cells.

In aspirin mice, the metastatic frequency has decreased compared to the mice in the drug, depending on the release of T cells from the suppression by TXA2.

“Despite progress in the treatment of cancer, many patients with early stage cancers, such as removing tumor surgery, which can be therapeutic, but later due to the potential growth of micromethstasis, but also in the body,

“Most of the immune system has been created to treat patients with metastatic cancer, but when the cancer first spreads, there is a unique window therapy of the opportunity for cancer cells to be vulnerable to immune attack,” he said.

“We hope that the treatments that target this vulnerability window will have a tremendous range in preventing recurrence in patients with primary cancer at risk.”

“It was an Eureka moment that we found that the TXA2 was a molecular signal that activates this repressive effect on T cells,” said Dr. Jay Young from the University of Cambridge.

“Before that, we were not aware of the consequences of our findings in understanding the metastatic aspirin anti -aspirin activity,” he said.

“It was a completely unexpected finding that passed us on a completely different research path from what we had anticipated,” he said.

“Aspirin or other drugs that can target this path have the potential to be cheaper than antibody -based therapies, so they are more accessible worldwide.”

Researchers are currently working with Professor Ruth Longley at the University of London College, leading the additive clinical test, to find out if aspirin can stop or delay primary cancers.

This trial supported by cancer research in the UK includes patients with breast, breast, stomach, stomach, prostate and intestinal cancer.

“This is an important discovery,” said Professor Longley.

“In a small part of people, aspirin can cause serious side effects, such as bleeding or gastric ulcer,” he said.

“Therefore, it is important to understand that people with cancer are likely to benefit from it and always talk to their doctor before aspirin.”

Alan Melcher, a professor of immunotherapy, translated at the Cancer Research Institute, London, said the side effects of aspirin are not trivial-such as gastric bleeding.

“This new study may help design better and more targeted drugs, which is harmful in the mechanism discovered here to do good things as Aspirin.”

Tanya Holland, director of research information on Cancer Research in the UK, said more work is needed.

“Currently, there are no national guidelines for the public population to use aspirin to prevent or treat cancer …

“British cancer research is funding similar research, including the Add-Aspirin test, the world’s largest clinical trial designed to look at aspirin as a way to prevent cancer after receiving cancer treatment. We are looking forward to seeing how research is developing,” he said.